| Biomarker ID | 237 |
| PMID | 18047674 |
| Year | 2007 |
| Biomarker | Prostate Specific Antigen (PSA) |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Cell Lines |
| Subjects | Humans |
| Regulation | Downregulated in Dasatinib Sensitive Cell Lines (>3 fold) |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include:-ID regulation of gene expression,Prostate cancer,Androgen receptor proteolysis and transcription regulation,Androgen receptor signaling, proteolysis, and transcription regulation,Insulin-like growth factor (IGF) activity regulation by insulin-like growth factor binding proteins (IGFBPs) |
| Experiment | Dasatinib Sensitive Vs Dasatinib Resistant Cell Lines |
| Type of Biomarker | Potential Predictive |
| Cohort | Dasatinib sensitive cell Lines (LNCaP, DU145, PC3, PWR1E, RWPE1, RWPE2, NB11, NB16, HPV10, HPV7,W99) and Dasatinib resistant cell lines (MDAPCa2b, 22Rv, VCaP, DUCaP, WPMY1) were analysed for the experiment. Data accesseble at: GSE9633 |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.05 |
| Method Used | Microarray |
| Clinical | No |
| Remarks | Effects of Dasatinib was checked on 16 cell lines. 3 predictive biomarkers were discovered - AR, PSA, CK5. uPA was found to be a surrogate marker and EphA2 was found to be a sensitivity marker. |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on human patient cohort |
| Technical Name | KLK3 |